Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Finished Goods (2020 - 2025)

Bioventus' Finished Goods history spans 6 years, with the latest figure at $61.0 million for Q4 2025.

  • For Q4 2025, Finished Goods fell 13.33% year-over-year to $61.0 million; the TTM value through Dec 2025 reached $61.0 million, down 13.33%, while the annual FY2025 figure was $61.0 million, 13.33% down from the prior year.
  • Finished Goods reached $61.0 million in Q4 2025 per BVS's latest filing, down from $74.4 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $75.0 million in Q3 2023 to a low of $31.5 million in Q3 2021.
  • Average Finished Goods over 5 years is $60.9 million, with a median of $65.9 million recorded in 2022.
  • Peak YoY movement for Finished Goods: skyrocketed 93.01% in 2021, then decreased 13.33% in 2025.
  • A 5-year view of Finished Goods shows it stood at $50.8 million in 2021, then surged by 30.52% to $66.3 million in 2022, then grew by 5.97% to $70.3 million in 2023, then rose by 0.15% to $70.4 million in 2024, then decreased by 13.33% to $61.0 million in 2025.
  • Per Business Quant, the three most recent readings for BVS's Finished Goods are $61.0 million (Q4 2025), $74.4 million (Q3 2025), and $73.0 million (Q2 2025).